B16-F10-OVA Syngeneic Model Service for Melanoma

The B16-F10-OVA syngeneic model of melanoma adds a defined ovalbumin antigen to the aggressive, poorly immunogenic B16-F10 melanoma, turning the field’s coldest solid tumor into a traceable platform for vaccine and combination-immunotherapy research in C57BL/6 hosts. Alfa Cytology delivers the complete B16-F10-OVA workflow—construct-verified cell banking, flank implantation, OT-I/OT-II-compatible designs, intervention scheduling and tetramer-based endpoint analysis—giving sponsors decision-ready preclinical datasets shaped to their program, strictly within a preclinical scope.

Overview of B16-F10-OVA Syngeneic Model for Melanoma

B16-F10-OVA answers a pointed question: what happens when a defined antigen is bolted onto a tumor famous for ignoring immunity? The parental B16-F10—selected through ten cycles of Fidler’s lung-colonization protocol from a 1954 spontaneous C57BL/6 melanoma—is poorly immunogenic, expresses MHC-I at low levels, grows with a 17-hour doubling time and metastasizes relentlessly. Engineering it to express chicken ovalbumin produced a line with dual antigen biology: the foreign model antigen, whose SIINFEKL epitope (OVA257–264) is displayed on H-2K^b and OVA323–339 on I-A^b, sits alongside the melanoma’s native differentiation antigens such as gp100—allowing model-antigen and tumor-antigen responses to be compared in the same tumor. Importantly, the construct landscape is plural: documented versions include lentiviral overexpression clones (Biocytogen’s 1-G12 and 1-G04), an ATCC pLX305 puromycin-resistance version (CRL-3686), the classic B16-OVA MO4 clone created for Falo and Rock’s 1995 Nature Medicine study, and transposon-based OVA-eGFP-neo integrations selected with G418. OVA expression demonstrably warms the tumor: subcutaneous implants show increased TIL infiltration with a significantly higher CD8⁺ fraction than wild-type B16-F10, and harvested tumors retain surface OVA—proof the antigen survives the in vivo passage.

Fig 1. Adoptive transfer of OVA-specific OT-II CD4+ T cells markedly reduces lung metastatic burden and extends survival in the B16-F10-OVA syngeneic metastatic melanoma model. (Liu, Qiao, et al., 2022)

In practice, two hundred thousand to half a million cells in the flank grow progressively—tracked by the 0.5 × long × short² formula—while the heavier MO4 dosing tradition (5–10 million cells, greater than 60% take) models long-established, invariably progressive disease. The line’s combination record is remarkable: adoptively transferred OT-I cells synergize with agonistic anti-CD137 (clone 1D8) in a CD8-dependent fashion; an antigen-specific bacterial vaccine combined with anti-PD-L1 rescued dysfunctional endogenous T cells and rejected long-established tumors—one of the cleanest demonstrations of checkpoint-enabled T-cell revival; the dsRNA mimic BO-110 restored antitumor immunity with OVA/OT-I readouts; and prior OVA vaccination protected against B16-OVA challenge months later. Caveats are specific: construct heterogeneity across sources demands explicit verification before use; antibiotic selection must be maintained to prevent antigen loss; parental fast kinetics compress windows; low baseline MHC-I tempers expectations; and the MO4 subline carries documented BXV-1 provirus—a biosafety flag for that stock.

Cell Line Information: B16-F10-OVA

Key characteristics of B16-F10-OVA and its documented constructions are summarized below.

Our Services

With in vivo oncology and T-cell-biology specialists guiding each stage and flow cytometry, tetramer staining and digital pathology in-house, Alfa Cytology configures every B16-F10-OVA engagement around the sponsor’s antigen-specific question—documenting the construct, maintaining selection pressure, and pairing interventions with dual-antigen readouts spanning OVA tracking and native melanoma antigens for clean, decision-grade preclinical data.

Workflow of B16-F10-OVA Syngeneic Model Construction

Construction of the B16-F10-OVA syngeneic model is an implantation workflow whose quality rests on construct-verified cells, vigorous C57BL/6 recipients and disciplined monitoring. A standard engagement proceeds as follows:

1. Source and qualify cells: B16-F10-OVA stocks are cleared by mycoplasma PCR and STR-authenticated, with the construct explicitly documented; OVA expression is confirmed by Western blot and SIINFEKL–H-2K^b staining (25-D1.16), selection is maintained through expansion, and luciferase labeling is titrated in vitro where imaging readouts are required.
2. Prepare recipients: C57BL/6 mice (typically 6–8 weeks old; OT-I/OT-II transgenic or congenically marked hosts where antigen-specific designs call for them) complete acclimation and health screening.
3. Prepare the inoculum: log-phase cells are harvested, washed, counted and resuspended in PBS (2 × 10⁵–5 × 10⁵ cells in 100 µL for standard flank implants; higher doses per the MO4 tradition where long-established disease is the design).
4. Implant: cells are injected subcutaneously into the flank with consistent anatomical positioning for reproducible caliper measurement.
5. Randomize: when tumors reach palpability, animals are assigned to groups balanced by tumor volume and body weight.
6. Dose and follow: test articles (checkpoint agents, vaccines, costimulatory antibodies, dsRNA immunomodulators) are administered on schedule; tumors are measured two to three times weekly using the 0.5 × long × short² formula, with body weight and survival logged; OT-I/OT-II transfer arms follow the documented day 3–7 window where designed.
7. Terminate and analyze: tumors are resected and weighed; tumor-infiltrating lymphocytes are analyzed by flow cytometry with H-2K^b–SIINFEKL tetramers and activation/exhaustion panels; sections are stained with 25-D1.16 and CD3 alongside melanin assessment; draining lymph nodes, spleen and lungs are examined; tissues enter histopathology and molecular analysis.

Fig 2. B16-F10-OVA Syngeneic Model construction workflow.

Case Study-B16-F10-OVA Syngeneic Model Development

Alfa Cytology maintains an active preclinical case-study file on the B16-F10-OVA platform: establishment-phase construct documentation and OVA-expression verification, in vivo growth kinetics at flank inocula, checkpoint-, vaccine- and dsRNA-based intervention studies with antigen-specific monitoring, and endpoint analyses combining tetramer staining, 25-D1.16 immunohistochemistry, native-antigen assessment and TIL phenotyping. Representative growth curves, T-cell tracking datasets and endpoint summaries can be shared upon request and will be updated as new programs conclude.

Why Choose Alfa Cytology?

B16-F10-OVA’s dual-antigen design and plural construct history reward careful sourcing and flexible execution—which is where Alfa Cytology invests:

• Construct-documentation discipline spanning the lentiviral, pLX305, MO4 and transposon lineages.
• Selection-maintained banking with Western blot and 25-D1.16 verification before every implantation.
• Dual-antigen endpoint design covering OVA tracking alongside native gp100/pmel biology.
• Checkpoint-rescue expertise reflecting the bacterial-vaccine/anti-PD-L1 precedent in this model.
• OT-I/OT-II logistics with tetramer-based TIL quantification in-house.
• Fast-kinetics scheduling calibrated to the parental 17-hour doubling tempo.
• One accountable project contact with milestone-by-milestone visibility.
• A strictly preclinical scope—every study is planned, executed and reported as non-clinical research.

Contact Us

Interested in the B16-F10-OVA syngeneic melanoma model for your next preclinical program? Reach out to us with your antigen-specific design, timeline and endpoint wish-list, and the Alfa Cytology team will respond with a customized plan covering model setup, OT-I/OT-II coordination and analysis workflow—contact us today and move your program forward with confidence.

For research use only. Not intended for any clinical use.